GNL Gut and Liver
  1. Eun Soo Kim. Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?. Gut and Liver 2021;15:149
    https://doi.org/10.5009/gnl210098
  2. Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon. Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function. Gut and Liver 2023;17:766
    https://doi.org/10.5009/gnl220159
  3. Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang. Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?. Gut and Liver 2022;16:138
    https://doi.org/10.5009/gnl210246
  4. Ohad Atia, Chagit Friss, Gili Focht, Ramit Magen Rimon, Natan Ledderman, Shira Greenfeld, Amir Ben-Tov, Yiska Loewenberg Weisband, Eran Matz, Yuri Gorelik, Yehuda Chowers, Iris Dotan, Dan Turner. Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN. 2024
    https://doi.org/10.1093/ibd/izae067
  5. Ann-Lorie Gagnon, William Beauchesne, Laurence Tessier, Charles David, Djamal Berbiche, Alexandre Lavoie, Alban Michaud-Herbst, Karine Tremblay. Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center. 2021;3
    https://doi.org/10.1093/crocol/otab049
  6. Ligia Yukie Sassaki, Daniela Oliveira Magro, Rogerio Saad-Hossne, Julio Pinheiro Baima, Cristina Flores, Lucianna Motta Correia, Lívia Medeiros Soares Celani, Maria De Lourdes De Abreu Ferrari, Patricia Zacharias, Marley Ribeiro Feitosa, Carlos Henrique Marques Dos Santos, Manoel Alvaro De Freitas Lins Neto, Abel Botelho Quaresma, Sergio Figueiredo De Lima Junior, Graciana Bandeira Salgado De Vasconcelos, Ornella Sari Cassol, Arlene Dos Santos Pinto, Gustavo Kurachi, Francisco de Assis Goncalves Filho, Rodrigo Galhardi Gasparini, Thaísa Kowalski Furlan, Wilson Roberto Catapani, Cláudio Saddy Rodrigues Coy, Vivian De Souza Menegassi, Marilia Majeski Colombo, Renata de Sá Brito Fróes, Fabio Vieira Teixeira, Antonio Carlos Moraes, Genoile Oliveira Santana, José Miguel Luz Parente, Eduardo Garcia Vilela, Natália Sousa Freitas Queiroz, Paulo Gustavo Kotze. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). BMC Gastroenterol 2022;22
    https://doi.org/10.1186/s12876-022-02341-7
  7. Zvonimir Petric, Joao Goncalves, Paulo Paixao. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. Pharmaceutics 2022;14:1766
    https://doi.org/10.3390/pharmaceutics14091766
  8. Hassan Karami, Farbod Ebadi Fard Azar, Kamran Bagheri Lankarani, Aziz Rezapour, Sulmaz Ghahramani, Abdolvahab Baghbanian. Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study. CDS 2023;18:484
    https://doi.org/10.2174/1574886317666220526153518
  9. Ahmed Salman, Mohamed A Salman, Ahmed Elewa, Asmaa M Awwad. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. 2024
    https://doi.org/10.7759/cureus.61547
  10. Brigid Pinnuck, Kate D. Lynch. Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis. Expert Opinion on Pharmacotherapy 2024;25:1835
    https://doi.org/10.1080/14656566.2024.2407022
  11. Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi. Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study. Gut and Liver 2022;16:764
    https://doi.org/10.5009/gnl210335
  12. Fabio Salvatore Macaluso, Marcello Maida, Mauro Grova, Federica Crispino, Giulia Teresi, Adele Orlando, Ambrogio Orlando. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therap Adv Gastroenterol 2021;14
    https://doi.org/10.1177/17562848211010668
  13. Ji-Eun Na, Yong-Eun Park, Jong-Ha Park, Tae-Oh Kim, Jong-Yoon Lee, Jong-Hoon Lee, Su-Bum Park, Seung-Bum Lee, Seung-Min Hong. Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study. JPM 2024;14:1066
    https://doi.org/10.3390/jpm14101066
  14. Othman Alharbi, Abdulrahman M. Aljebreen, Nahla A. Azzam, Majid A. Almadi, Maria Saeed, Baraa HajkhderMullaissa, Hassan Asiri, Abdullah Almutairi, Yazed AlRuthia. Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study. JCM 2022;11:4157
    https://doi.org/10.3390/jcm11144157
  15. Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Han, Jaeyoung Chun, Hyun Soo Kim. Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis. 2023;57:601
    https://doi.org/10.1097/MCG.0000000000001715
  16. Camilla de Almeida Martins, Matheus Freitas Cardoso de Azevedo, Alexandre Sousa Carlos, Aderson Omar Mourão Cintra Damião, Carlos Walter Sobrado Junior, Sergio Carlos Nahas, Natália Sousa Freitas Queiroz. Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients. Therap Adv Gastroenterol 2023;16
    https://doi.org/10.1177/17562848231210053
  17. A. V. Levitskaya, E. A. Belousova, E. Yu. Lomakina, M. V. Teberdieva. Comparative efficacy and survival of biologics in inflammatory bowel disease in different lines of therapy: the clinician’s view of the problem. Koloproktologiâ 2025;24:103
    https://doi.org/10.33878/2073-7556-2025-24-1-103-114
  18. Mahmoud E. Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa R. Askar, Gamal A. Omran, Marwa A. El-Mohamdy, Radwa S. Hagag. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacol 2024;32:3259
    https://doi.org/10.1007/s10787-024-01508-w
  19. Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu, Maya A. Eicher. Therapeutic Antibodies in Medicine. Molecules 2023;28:6438
    https://doi.org/10.3390/molecules28186438
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd